Table 2 Change from baseline in other blood pressure parameters at Week 26
|  | Placebo (n = 504) | Ertugliflozin 5 mg (n = 519) | Ertugliflozin 15 mg (n = 510) |
|---|---|---|---|
Pulse pressure, mmHga | |||
 Baseline mean (SD)b | 51.8 (12.1) | 52.5 (11.3) | 52.1 (11.2) |
 LS mean change from baseline (95% CI) | − 0.8 (− 1.7, 0.0) | − 2.7 (− 3.5, − 1.9) | − 2.9 (− 3.8, − 2.1) |
 Placebo-adjusted LS mean change from baseline (95% CI) | – | − 1.9 (− 3.0, − 0.8) | − 2.1 (− 3.3, − 1.0) |
Mean arterial pressure, mmHga | |||
 Baseline mean (SD)b | 95.2 (8.7) | 96.0 (8.5) | 95.8 (8.1) |
 LS mean change from baseline (95% CI) | − 0.3 (− 1.0, 0.4) | − 2.8 (− 3.4, − 2.1) | − 2.65 (− 3.3, − 2.0) |
 Placebo-adjusted LS mean change from baseline (95% CI) | – | − 2.4 (− 3.4, − 1.5) | − 2.3 (− 3.2, − 1.4) |
Double product, mmHg × bpma | |||
 Baseline mean (SD)c | 9409.2 (1536.9) | 9544.7 (1668.6) | 9480.5 (1571.1) |
 LS mean change from baseline (95% CI) | − 44.0 (− 161.7, 73.7) | − 479.9 (− 594.5, − 365.3) | − 514.1 (− 630.8, − 397.4) |
 Placebo-adjusted LS mean change from baseline (95% CI) | – | − 435.9 (− 593.6, − 278.2) | − 470.0 (− 629.3, − 310.8) |